News
-
-
-
-
PRESS RELEASE
Biotests’ positive fibrinogen phase III trial results published in The Lancet’s eClinicalMedicine
Biotest AG announces positive phase III trial results for fibrinogen concentrate BT524 in reducing bleeding, with potential regulatory approval in Europe and U.S. pending. Study data to be presented at ISTH 2025 Congress -
-
-
-
-
-
PRESS RELEASE
EQS-Adhoc: Biotest AG: Change of the Chief Executive Officer (CEO) of Biotest AG
Biotest AG announces change of CEO. Dr. Jörg Schüttrumpf appointed new CEO, succeeding Peter Janssen by mutual agreement. Supervisory Board thanks Mr. Janssen for his past commitment. Dr. Schüttrumpf previously served on the Management Board